Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMarcelo Orias, MD, PhD
Associate Professor AdjunctAbout
Research
Publications
2025
Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1
Rosende A, Romero C, DiPette D, Brettler J, Van der Stuyft P, Satheesh G, Perel P, Chapman N, Moran A, Schutte A, Sharman J, Irazola V, Huffman M, Campbell N, Salam A, Lanas F, Coca A, Garcia-Zamora S, Ferreiro A, Lopez-Jaramillo P, Rico-Fontalvo J, Ridley E, Picone D, Flood D, Piñeiro D, Ojeda C, Rodriguez G, Wellmann I, Orias M, Rivera M, Reyes M, Onuma O, Ramroop S, Khan T, Gonzalez Y, Barroso W, Plavnik F, Zuniga E, Grassani A, Tajer C, Zaidel E, Marin M, Cyr-Philbert S, Amorin I, Aguilera M, Bortolotto L, Avezum A, Ribeiro A, Tobe S, Aumala T, Angell S, Lavados P, Martins S, Echeverri A, Jaffe M, Prabhakaran D, Parati G, Zhang X, Rodgers A, Yusuf S, Whelton P, Ordunez P. Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1. Global Heart 2025, 20: 45. PMID: 40454106, PMCID: PMC12124280, DOI: 10.5334/gh.1428.Peer-Reviewed Original ResearchConceptsClinical pathwayNon-physician health workersTeam-based careImprove care deliveryReduce care fragmentationPrimary care settingPrimary health settingsCare of hypertensionGlobal Hearts InitiativeCommunity-based screeningEvidence-based interventionsManagement of risk factorsHigher CVD riskLower blood pressure thresholdHigh CVD risk patientsCardiovascular diseaseChronic kidney diseasePhase 1Blood pressure thresholdsHealth equityCare fragmentationHearts InitiativePrimary careCare deliveryHealth settings
2023
It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives
Campbell N, Whelton P, Orias M, Cobb L, Jones E, Garg R, Willliams B, Khan N, Chia Y, Jafar T, Ide N. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. Journal Of Hypertension 2023, 41: 683-686. PMID: 36723484, PMCID: PMC10090307, DOI: 10.1097/hjh.0000000000003385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSpot urine samplesSodium intakeIndividual sodium intakeWorld Hypertension LeagueHealth outcomesUrine samplesHealth outcome associationsOutcome associationsInternational SocietyDietary sodiumHealth OrganizationIntakeHypertensionHealth impactsShort durationOutcomesAssociationSubstantial controversyLiterature reviewPolicy statements
2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysisBedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension
Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski M. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Journal Of Hypertension 2022, 40: 1847-1858. PMID: 35983870, DOI: 10.1097/hjh.0000000000003240.Peer-Reviewed Original ResearchConceptsAntihypertensive drugsAntihypertensive medicationsBedtime dosingOutcome trialsDrug dosingClinical practiceEfficient medical interventionsHypertension position paperMorning BP surgeNight-time hypertensionAntihypertensive drug therapyAntihypertensive drug treatmentSingle morning doseBlood pressure profileEffective treatment strategiesWorld Hypertension LeagueInternational SocietyAntihypertensive treatmentBedtime administrationBP controlBP surgeMorning doseMorning dosingCardiovascular eventsAdverse prognosis2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N, Neal B, Cohn J, Cobb LK, Webster J, Trieu K, He FJ, McLean RM, Blanco-Metzler A, Woodward M, Khan N, Kokubo Y, Nederveen L, Arcand J, MacGregor GA, Owolabi MO, Lisheng L, Parati G, Lackland DT, Charchar FJ, Williams B, Tomaszewski M, Romero CA, Champagne B, L’Abbe M, Weber MA, Schlaich MP, Fogo A, Feigin VL, Akinyemi R, Inserra F, Menon B, Simas M, Neves MF, Hristova K, Pullen C, Pandeya S, Ge J, Jalil JE, Wang JG, Wideimsky J, Kreutz R, Wenzel U, Stowasser M, Arango M, Protogerou A, Gkaliagkousi E, Fuchs FD, Patil M, Chan AW, Nemcsik J, Tsuyuki RT, Narasingan SN, Sarrafzadegan N, Ramos ME, Yeo N, Rakugi H, Ramirez AJ, Álvarez G, Berbari A, Kim CI, Ihm SH, Chia YC, Unurjargal T, Park HK, Wahab K, McGuire H, Dashdorj NJ, Ishaq M, Ona DID, Mercado-Asis LB, Prejbisz A, Leenaerts M, Simão C, Pinto F, Almustafa BA, Spaak J, Farsky S, Lovic D, Zhang XH. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal Of Human Hypertension 2022, 37: 428-437. PMID: 35581323, PMCID: PMC9110933, DOI: 10.1038/s41371-022-00690-0.Peer-Reviewed Original ResearchImplementación de la Iniciativa HEARTS en Argentina: primeros resultados
Rodriguez G, Rosende A, Prado C, Mariño R, Irazola V, DiPette D, Orias M, Arcila G, Laspiur S. Implementación de la Iniciativa HEARTS en Argentina: primeros resultados. BULL PAN AM HEALTH ORGAN 2022, 46: e181. PMID: 36160765, PMCID: PMC9491484, DOI: 10.26633/rpsp.2022.181.Peer-Reviewed Original ResearchCombination therapyHearts InitiativePrimary health care centersStandardized treatment protocolMain risk factorsHealth care centersCause of mortalityBlood pressure measurement devicesArterial hypertensionRisk factorsCare centerTherapy levelsCardiovascular diseaseHealth centersTreatment protocolHealth teamsBaseline valuesParadoxical decreasePressure measurement deviceClinical competencyPeriod of restrictionHypertensionGeneralized reductionCOVID-19Therapy
2021
Is Isolated Diastolic Hypertension an Important Phenotype?
Romero CA, Tabares AH, Orias M. Is Isolated Diastolic Hypertension an Important Phenotype? Current Cardiology Reports 2021, 23: 177. PMID: 34657205, PMCID: PMC8753786, DOI: 10.1007/s11886-021-01609-w.Peer-Reviewed Original ResearchConceptsNarrow pulse pressureDiastolic hypertensionCardiovascular riskPulse pressureLong-term cardiovascular riskRecent FindingsRecent guidelinesHypertension subgroupIDH definitionsIDH prevalenceHypertensive patientsYounger patientsRisk stratificationEpidemiological characteristicsTherapeutic decisionsPharmacological interventionsHypertension phenotypesCutoff levelHypertensionImportant subgroupPatientsPathophysiologyRiskSubgroupsIDHLong termASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients
Coyne D, Singh A, Lopes R, Bailey C, Dimino T, Huang C, Connaire J, Rastogi A, Kim S, Orias M, Shah S, Patel V, Cobitz A, Wanner C. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 191-191. DOI: 10.1681/asn.20213210s1191b.Peer-Reviewed Original ResearchErratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]
Morales-Salinas A, Olsen M, Kones R, Kario K, Wang J, Beilin L, Weber M, Yano Y, Burrell L, Orias M, Dzudie A, Lavie C, Ventura H, Sundström J, de Simone G, Coca A, Rumana U, Marrugat J. Erratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]. Current Problems In Cardiology 2021, 46: 100877. PMID: 34148707, DOI: 10.1016/j.cpcardiol.2021.100877.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLlamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020
Campbell NR, Schutte AE, Varghese CV, Ordunez P, Zhang XH, Khan T, Sharman JE, Whelton PK, Parati G, Weber MA, Orías M, Jaffe MG, Moran AE, Plavnik FL, Ram VS, Brainin M, Owolabi MO, Ramirez AJ, Barbosa E, Bortolotto LA, Lackland DT. Llamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020. BULL PAN AM HEALTH ORGAN 2021, 45: 1. PMID: 33643404, PMCID: PMC7905751, DOI: 10.26633/rpsp.2021.26.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements